• The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies.
• The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems from the model library. This significantly improves resolution in identifying the differentiating advantages of multi-target combinations—uncovering subtle distinctions across genes, molecules, cells, tissues, and clinical phenotypes.

BOSTON and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ — HKeyBio, a global leading CRO specializing in preclinical and translational research for autoimmune and allergic disease drug development, has officially launched the upgraded HKEY-AIDMD 3.0 platform. This platform includes: (1) a four-dimensional model library of nearly 300 autoimmune and allergic disease models, and (2) a comprehensive spatiotemporal single-cell and spatial omics database derived from these models. The platform is designed to significantly enhance prediction accuracy for clinical translation of multi-target combination therapies.

Autoimmune and allergic diseases stem from dysregulated immune networks across three major immunological domains: multiple cellular components, diverse cytokine networks, and interconnected signaling pathways. These conditions involve aberrant activity of immune cell populations such as T cells, B cells, dendritic cells, and granulocytes; dysregulated cytokines including IL-6, IL-4, TNF; and perturbed signaling pathways such as JAK/STAT, NF-κB, BTK, along with mechanisms of immune tolerance. Since single-target drugs may demonstrate limited efficacy in certain patient populations, multi-target combinations can more comprehensively modulate pathological networks and improve therapeutic outcomes. Moreover, due to disease heterogeneity, multi-target therapies can more precisely match patient-specific pathogenic profiles, supporting personalized treatment strategies.

However, multi-target drug development faces major technical and clinical challenges. The number of possible combinations increases exponentially due to the diversity of targets, dosing regimens, and mechanisms of action. With limited resources, prioritizing the most effective and safest combinations is an urgent unmet need. Achieving optimal combinations requires accurate mapping of key pathogenic nodes within disease networks and identifying predictive biomarkers for treatment response.

HKeyBio’s newly upgraded HKEY-AIDMD 3.0 provides a practical solution to the “optimal multi-target combination” challenge. Built upon deep mechanistic insights into autoimmune and allergic diseases, HKeyBio has developed four-dimensional model pools across multiple species, strains, and induction strategies to simulate various disease subtypes and endotypes. These model pools enable evaluation of in vivo interactions, feedback mechanisms, and synergy of multi-target combinations. Using systems biology approaches, including gene regulatory networks, protein-protein interaction networks, and pathway topology analysis, HKeyBio identifies key nodal and bottleneck targets in disease networks. Machine learning methods further support predictive modeling of combination outcomes and discovery/validation of biomarkers such as gene signatures, single-cell immune profiles, and cytokine panels.

The HKEY-AIDMD 3.0 platform not only enhances predictive value for multi-target efficacy but also significantly boosts developability and commercial partnering value. By integrating multi-indication 4D model pools with spatiotemporal omics, the platform offers critical support for new drug development in rheumatology, immunology, and allergy. It improves mechanistic accuracy, provides high-resolution multi-dimensional biomarker discovery, and increases reliability in predicting therapeutic responses across multiple pathways.

About the HKeyBio HKEY-AIDMD 3.0 Platform

The HKEY-AIDMD 3.0 model library covers nearly 300 autoimmune and allergy-related disease models. For major indications, HKeyBio has built 4D model pools that simulate clinical heterogeneity to support mechanism-based model selection for multi-target combination evaluation. These include dermatologic models (atopic dermatitis, urticaria, pruritus, hidradenitis suppurativa, psoriasis), respiratory models (asthma, COPD, pulmonary fibrosis), gastrointestinal models (IBD, Crohn’s disease), and rheumatologic models (SLE, cutaneous lupus, Sjögren’s syndrome, rheumatoid arthritis, systemic sclerosis, multiple sclerosis), among many others.

The HKEY-AIDMD 3.0 omics database encompasses spatiotemporal single-cell and spatial omics across tissues and immune compartments from all models. Using systems biology methods—including gene expression networks, protein–protein interaction networks, and signaling topology analysis—combined with machine learning, the platform predicts multi-target drug combination effects and validates biomarkers for efficacy and safety, dramatically improving the resolution in differentiating target-combination strategies.

HKeyBio is an industry-leading CRO specializing in pharmacology and translational research for autoimmune diseases—focused, dedicated, and deeply experienced in autoimmune innovation.
For more information, please visit www.hkeybio.com

For inquiries, please contact: us.bd@hkeybio.com

• Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

• BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood

FLORENCE, Italy and NEW YORK, Nov. 24, 2025 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, today announced that the company will present new data related to ELZONRIS® (tagraxofusp-erzs) at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, December 6-9^th.

The presentations include an oral session highlighting results from a triplet therapy combining tagraxofusp, azacitidine, and venetoclax, which demonstrated both efficacy (high response and bridge to transplant rates) and tolerability in individuals with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

“At Menarini Stemline, our commitment to transforming the lives of people living with difficult-to-treat cancers is unwavering,” said Elcin Barker Ergun, CEO of the Menarini Group. “These data demonstrate that tagraxofusp plays an important role in both monotherapy and combination settings for the treatment of BPDCN, and that it also has potential to help patients living with other aggressive hematologic malignancies, where more effective treatment options are desperately needed.”

See below for full details of the Menarini Group/Stemline Therapeutics’ upcoming presentations and publication:

American Society of Hematology (ASH) Annual Meeting 2025

*Denotes investigator sponsored research or collaborative research.

ELZONRIS was approved by the FDA in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. In January 2021, ELZONRIS was approved by the European Commission. 

About BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow and blood. It can also affect other parts of the body, such as the lymph nodes, spleen, liver and central nervous system. Approximately 85% to 90% of patients develop skin lesions as a first sign of BPDCN. BPDCN affects all people of all races and geographic locations, with the global prevalence likely in the range of 0.4 – 0.5 per 100,000 people annually. While BPDCN affects both men and women of all ages, 75% of cases occur in men, with a median age at onset of 60-70 years. A key characteristic of BPDCN cancer cells is their high expression of a protein called CD123, which can be observed on the surface of the cells. This makes CD123 a crucial diagnostic marker as well as a prime target for precision therapies to strike the cancer directly.

About ELZONRIS^® (tagraxofusp-erzs)

U.S. Indication: ELZONRIS (tagraxofusp-erzs) is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

Full prescribing information for the U.S. can be found at www.elzonris.com.

IMPORTANT SAFETY INFORMATION, ELZONRIS®

Boxed WARNING: CAPILLARY LEAK SYNDROME

• Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended.

Warnings and Precautions

Capillary Leak Syndrome

Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with ELZONRIS. In patients receiving ELZONRIS in clinical trials, the overall incidence of CLS was 53% (65/122), including Grade 1 or 2 in 43% (52/122) of patients, Grade 3 in 7% (8/122) of patients, Grade 4 in 1% (1/122) of patients, and four fatalities (3%). The median time to onset was 4 days (range – 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.

Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability.

Hypersensitivity Reactions

ELZONRIS can cause severe hypersensitivity reactions. In patients receiving ELZONRIS in clinical trials, hypersensitivity reactions were reported in 43% (53/122) of patients treated with ELZONRIS and were Grade ≥ 3 in 7% (9/122). Manifestations of hypersensitivity reported in ≥ 5% of patients include rash, pruritus, and stomatitis. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur.

Hepatotoxicity

Treatment with ELZONRIS was associated with elevations in liver enzymes. In patients receiving ELZONRIS in clinical trials, elevations in ALT occurred in 79% (96/122) and elevations in AST occurred in 76% (93/122). Grade 3 ALT elevations were reported in 26% (32/122) of patients. Grade 3 AST elevations were reported in 30% (36/122) and Grade 4 AST elevations were reported in 3% (4/122) of patients. Elevated liver enzymes occurred in the majority of patients in Cycle 1 and were reversible following dose interruption.

Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Withhold ELZONRIS temporarily if the transaminases rise to greater than 5 times the upper limit of normal and resume treatment upon normalization or when resolved.

Adverse Reactions

Most common adverse reactions (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, pyrexia, peripheral edema, and weight increase. Most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

 Please see full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com. 

About Stemline Therapeutics Inc.

Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.

– Results Underscore Need for Continued Research and Diverse Treatment Pipeline

CHICAGO, Nov. 24, 2025 /PRNewswire/ — The Alzheimer’s Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer’s disease.

“While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease,” said Joanne Pike, DrPH, Alzheimer’s Association president and chief executive officer. “The data from every clinical trial, regardless of outcome, is vital to accelerating our understanding of this disease and helps inform the next generation of clinical trials. We remain optimistic about the future of Alzheimer’s treatment and prevention, as the scientific landscape continues to diversify and expand.”

The company said, “While treatment with semaglutide resulted in improvement of Alzheimer’s disease-related biomarkers in both trials, this did not translate into a delay of disease progression.” The evoke and evoke+ trials were large-scale, long-term international clinical trials. More than 3,800 people ages 55-85 diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, (referred to as stage 3 and 4 of Alzheimer’s disease), were enrolled.

“These results will help us refine our understanding of this class of drugs,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “Though this semaglutide pill did not help against Alzheimer’s, the field will continue to investigate this class of drugs, as they may act differently. And, the Alzheimer’s Association remains a fierce leader for this type of innovative research, and we believe it’s critical to continue investigating diverse approaches to treatment and prevention.”

The Alzheimer’s treatment pipeline is robust and full of hope. An annual evaluation of the drug development pipeline published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions in early 2025, shows there are 182 active clinical trials evaluating 138 novel drugs. The Alzheimer’s Association, through its “Part the Cloud” program, provides strategic funding to advance promising investigational Alzheimer’s therapies into clinical trials. The treatment targets are varied, which is important given the growing consensus that effective treatment and prevention of Alzheimer’s is likely to be a personalized combination of multiple interventions.

For people living with early Alzheimer’s, approved treatments are available. We urge individuals to talk to their doctor about these options. Individuals can also talk to their doctor about participating in clinical trials, or visit the Alzheimer’s Association’s TrialMatch for more information.

The Association appreciates these topline results and looks forward to hearing a deeper dive into the data at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in December.

About the Alzheimer’s Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.

RIYADH, Saudi Arabia, Nov. 24, 2025 /PRNewswire/ — Dar Global, the London-listed international real estate developer, marked a major milestone today by ringing the opening bell at the London Stock Exchange (LSE). The ceremony celebrates the company’s transition to the Equity Shares (Commercial Companies) category and underscores its position as the first Saudi-born business to complete such a move on the LSE’s Main Market—opening a new channel for global investment into Saudi Arabia’s rapidly growing real estate sector.

DAR GLOBAL RINGS THE LONDON STOCK EXCHANGE OPENING BELL AS SAUDI ARABIA REAL ESTATE OPENS TO THE WORLD

Reinforcing its Saudi roots, Dar Global has established its global operations headquarters in Riyadh, approved by the Ministry of Investment of Saudi Arabia. From the new HQ, the company will oversee its international portfolio spanning the U.S., U.K., Spain, Greece, Qatar, Oman and the UAE, positioning Riyadh as the strategic centre of its global expansion.

Saudi Arabia will open freehold property ownership to all nationalities on January 1, 2026, unlocking one of the world’s largest real estate markets. With its financial listing in London and its headquarters now anchored in Riyadh, Dar Global is positioned to connect global investors to this landmark moment.

Following the LSE ceremony, Dar Global’s leadership travelled to Washington, D.C., to participate in the U.S.–Saudi Investment Forum, meeting policymakers and investors to highlight new opportunities emerging in the Kingdom. The message across both capitals was consistent: Saudi real estate is opening to the world—and international capital is ready.

Ziad El Chaar, CEO of Dar Global, said: “The world has been watching Saudi Arabia; now it can participate. Our listing in London and our engagement with global investors reflect our mission to build a bridge between international capital and Saudi’s most promising real estate opportunities. When freehold opens in 2026, a new chapter in global investment begins—and Dar Global is bringing it to life.”

This milestone aligns with Dar Global’s expansion in Saudi Arabia, including major land acquisitions and flagship developments in Riyadh and Jeddah. The company’s portfolio has grown to a Gross Development Value (GDV) of US$19 billion, supported by global advisors including Rothschild & Co.

Dar Global has partnered with more than ten world-renowned luxury brands—including Aston Martin, Automobili Lamborghini, ELIE SAAB, Pagani Automobili, Fendi, Missoni, W Hotels and Marriott Residences—to deliver distinctive, lifestyle-led developments worldwide.

DAR GLOBAL RINGS THE LONDON STOCK EXCHANGE OPENING BELL AS SAUDI ARABIA REAL ESTATE OPENS TO THE WORLD

TAMPA BAY, Fla., Nov. 24, 2025 /PRNewswire/ — Devicie, a leader in optimized Microsoft Intune deployment and maintenance solutions, today announced it is a Secure Access Trailblazer award finalist in the Microsoft Security Excellence Awards. The company was honored among a global field of industry leaders that demonstrated success across the security landscape during the past 12 months.

“We were recently recognized as a finalist for the Microsoft for Startups Partner of the Year Award, and now as a Secure Access Trailblazer,” said Shane Harding, Chief Executive Officer at Devicie. “We aligned our efforts early on with Microsoft and that decision continues to bear fruit for Devicie as our automation-first approach enables partners and customers to unlock the full potential of Microsoft Intune, achieving security, compliance and efficiency at scale, while freeing IT teams to focus on innovation.”

At the Microsoft Security Excellence Awards on January 26, 2026, Microsoft will celebrate finalists in 6 award categories honoring partner trailblazers, solution innovators, customer and technology champions and changemakers. This is the sixth year Microsoft is recognizing partners for their outstanding work in the security landscape. All finalists are members of the Microsoft Intelligent Security Association (MISA), an ecosystem of leading security vendors comprised of software development companies and services partners that have integrated their security products and services with Microsoft’s security technology.

“I’m very pleased to extend my warmest congratulations to this year’s finalists for the Microsoft Security Excellence Awards. These are presented each year to recognize the outstanding achievements of our Microsoft Intelligent Security Association members as they improve customers’ ability to identify and respond to security threats. Our community is made up of the most reliable and trusted security vendors worldwide. This year we received hundreds of quality submissions from partners and Microsoft stakeholders, so this year’s finalists stood out in a crowd of exceptional talent. It’s my pleasure to acknowledge and celebrate their work over the past year,” said Maria Thomson, Director, Microsoft Intelligent Security Association.

MISA was established to bring together Microsoft leaders, software development companies and services partners to work together to defeat security threats and make the world a safer place. The industry veterans in MISA and Microsoft will vote to select the winners of the Microsoft Security Excellence Awards, providing an opportunity for colleagues to honor their peers for delivering exceptional work to our shared customers.

About Devicie

Intune automation. Intune at scale. Intune that just works.

Devicie transforms Microsoft Intune into an automated, always-optimized endpoint management platform. With zero-touch configuration, advanced security, built-in compliance reporting, and ongoing optimization, Devicie eliminates complexity and accelerates outcomes for IT teams and managed service providers. By reducing manual workloads and standardizing management across tenants, Devicie helps organizations scale securely, improve profitability, and free technical teams to focus on higher-value initiatives.

Devicie is available globally through trusted distribution partners including Pax8, TD SYNNEX, Microsoft, and Crayon. Learn more at www.devicie.com.

For more information, press only:

Miluse Vejdani, Channel Marketing Director, +1 (617) 640-3802, Miluse.vejdani@devicie.com

Product or service names mentioned herein may be the trademarks of their respective owners.

###

Macao’s science and tech innovation enterprises deepen global integration and strengthen international ties

MACAO, Nov. 24, 2025 /PRNewswire/ — Jointly organised by Sands China and the Macao Economic and Technological Development Bureau (DSEDT), the five-day Macao Technological Innovation Exploration in Lisbon has successfully concluded. Supported by the Macao Science and Technology Development Fund (FDCT), and coordinated by the Sands Resorts Incubation Centre, the Nov. 10-14 trip was aimed at promoting the long-term growth of Macao’s technological innovation industry and fostering industry exchange between Macao and Portugal through a variety of activities and opportunities.

The trip’s 38-member delegation comprised representatives from 25 DSEDT-certified Macao enterprises, Macao startups incubated within the National Co-working Space scheme, and the organising entities. The visit gave all a valuable opportunity to gain exposure to emerging trends, technologies and industry insights, to exchange ideas with industry pioneers, and to explore how Lisbon’s tech and innovation ecosystem can benefit the integrated resort and technology industries in Macao, yielding fruitful results.

“Last year’s inaugural trip to Lisbon was widely acclaimed,” said Grant Chum, chief executive officer and executive director of Sands China Ltd. “This year, the five-day trip returned with even greater impact, providing a forward-looking international platform for a new cohort of Macao enterprises to broaden their horizons. It injected fresh momentum into innovation while establishing meaningful connections with Lisbon companies and achieving tangible outcomes. Renowned as an annual global technology event, the Web Summit was one of the highlights of this trip. This year, the summit drew more than 71,000 visitors from 157 countries, demonstrating its global influence and giving delegates an opportunity to gain knowledge of advanced technology and forge connections with their counterparts.

“Our gratitude goes to the Macao Economic and Technological Development Bureau and the Macao Science and Technology Development Fund for their collaboration and support to make this trip possible. Looking ahead, we will continue leveraging our Sands Resorts Incubation Centre to align with the Macao SAR government’s policies and direction in promoting ‘tourism + technology’ and capitalise on Macao’s role as a platform between China and Portuguese-speaking countries to contribute to the city’s diversified economic development.”

The Macao Economic and Technological Development Bureau said in a written statement: “As an important gateway for China’s opening up to the world, Macao enjoys unique advantages including the ‘One Country, Two Systems’ framework, free-port status, a separate customs territory, free flow of capital and information, and close ties with Portuguese-speaking countries. Macao’s technology research industrial park currently under planning will be positioned as a launchpad for the Chinese mainland’s high-quality tech enterprises to expand overseas, a service hub for cutting-edge international tech projects to establish a presence, and a local base for integration of industry, academia, and research. This will further enhance Macao’s own capacity for technological innovation and accelerate its economic transformation and upgrading through innovation-driven development.

“This delegation visit serves as a two-way platform. On one hand, it enables Macao’s tech enterprises to directly understand the latest innovation trends in Portugal and Europe, broadening their international perspective; on the other hand, it fosters deep cooperation with Portuguese-speaking countries and the global industry. Through on-site exchanges, Macao enterprises are encouraged to refine their research and development direction, allowing outstanding projects to bring in foreign investment and go global via Macao, helping the city become a key hub for the convergence of domestic and international technological resources.”

The itinerary began with the Web Summit, the world’s largest technology conference, held annually in Lisbon to bring together the world’s leading experts, innovators, business executives and investors. The Macao delegation attended keynote speeches, masterclass sharing sessions, and forums on artificial intelligence and robotics, exploring cutting-edge technologies and industry applications and connecting with global tech leaders in the process.

A Technology Business Networking Forum hosted by Sands China promoted cooperation and innovation within the technology industry, connecting Macao enterprises with each other and their industry counterparts in Lisbon. The curated networking event featured presentations, panel discussions, and a networking dinner. By sharing experiences, discussing trends and showcasing technologies, it provided a communication platform for delegates to expand their networks and find potential cooperation opportunities.

The nine-panellist forum was composed of four Portuguese enterprises and five tech companies from Macao. Among them were Macao enterprises Vastcom and AKL, who had both participated in last year’s inaugural Lisbon trip; they joined a panel discussion with Rui Falcão, co-founder and CEO of COREangels, to share their experiences and achievements. Additionally, three Macao companies and two from Portugal gave presentations that showcased their business models, opening up opportunities for collaboration.

Paulo Rios de Oliveira, executive board member of the Portuguese Trade and Investment Agency (AICEP), attended the forum and expressed strong support: “I am pleased to join you on behalf of AICEP and to contribute to this shared effort of building bridges and creating opportunities for innovation and business partnership. This forum reflects a common purpose – to strengthen ties, to promote technological development, and to generate value for our companies and communities. Portugal and China share a long history of exchange and mutual understanding. This commitment was reaffirmed recently during the visit of the Portuguese prime minister to China, including to Macao, where cooperation in innovation, advanced industries and sustainable development was highlighted as a shared strategic priority. Macao continues to play a unique role as a bridge of trust, connecting Portugal, China and the Portuguese-speaking world. This bridge is not only cultural. It is institutional and economical, and it provides a strong basis for collaboration growing forward.”

The delegation made structured visits to Portuguese enterprises, where they gained an in-depth understanding of innovative models and practical experiences, established connections, and promoted exchange and cooperation:

• Bhout – Developer of a smart punching bag powered by AI and real-time performance analytics, creating gamified fitness experiences for gyms, hotels, and cooperations.
• Lipolis – Lisbon’s innovation hub supporting startups and established companies in technology and health sectors with programmes for business acceleration, training, and networking.

Finally, Sands China hosted a Concrete Opportunities Workshop, engaging all delegates in collaborative discussions on opportunities for innovation. It featured Manuel Tanger, faculty member in Disruption, Innovation and Entrepreneurship at Singularity University Portugal. He introduced the innovation landscape in Lisbon, provided insights on working with startups, and guided participants on a collaborative exploration to map out innovation opportunities and determine next steps.

The Macao Technological Innovation Exploration in Lisbon is part of Sands China’s support of the Macao SAR government’s promotion of the long-term and sustainable development of smart tourism and high-tech industries. A total of 42 local enterprises have gone to Portugal on the 2024 and 2025 tours. Through such initiatives, Sands China hopes to further integrate tourism and modern technology by supporting the research and development of new high-tech local products, in contribution to Macao’s development as a world centre of tourism and leisure.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company’s integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner Macao^®. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company’s portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, the Londoner Theatre and the Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company’s Cotai Strip portfolio has the goal of contributing to Macao’s transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:

Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: mabel.wu@sands.com.mo 

Jesse Chiang
Tel: +853 8118 2054
Email: jesse.chiang@sands.com.mo